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Abstract 
Myeloid leukaemia’s share the common characteristics of being stem cell-derived clonal diseases, 
characterised by excessive proliferation of one or more myeloid lineage. Chronic myeloid leukaemia 
(CML) arises from a genetic alteration in a normal haemopoietic stem cell (HSC) giving rise to a 
leukaemic stem cell (LSC) within the bone marrow (BM) ‘niche’. CML is characterised by the presence 
of the oncogenic tyrosine kinase fusion protein BCR-ABL, which is responsible for driving the disease 
through activation of downstream signal transduction pathways. Recent evidence from our group and 
others indicates that important regulatory networks involved in establishing primitive and definitive 
haemopoiesis during development are reactivated in myeloid leukaemia, giving rise to an LSC 
population with altered self-renewal and differentiation properties. In this review we explore the role 
BMP signalling plays in stem cell pluripotency, developmental haemopoiesis, HSC maintenance and 
the implication of altered BMP signalling on LSC persistence in the BM niche. Overall we highlight how 
the BMP and Wnt pathways converge to alter the Cdx-Hox axis and the implications of this in the 
pathogenesis of myeloid malignancies.  
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The bone morphogenic protein (BMP) pathway 
The bone morphogenic protein (BMP) ligands are part of the transforming growth factor-β (TGFβ) 
superfamily, which includes TGFβs, Activins/Inhibins, Nodal, Myostatin, and Anti Mullerian Hormone 
(AMH). BMP ligands possess different affinities for the BMP receptors, which determine their 
specificity of action [1, 2]. Activation of the BMP pathway occurs either in a canonical SMAD-
dependant or SMAD-independent manner. The former is dependent on SMAD proteins for regulation 
whereas the latter involves extracellular signal-regulated kinases (ERK), Janus N-terminal kinase 
(JNK) and p38 Mitogen-activated protein kinase (MAPK) pathways. The canonical BMP pathway 
relies on a series of signal transduction steps which is initiated when BMP ligands bind to type II 
receptors. Ligand binding then leads to the heterodimerization of the type I and type II receptors. This 
in turn phosphorylates the corresponding receptor regulated SMADs (R-SMADs) and drives the 
formation of an R-SMAD-Co-SMAD complex. This complex translocates to the nucleus where it binds 
to relevant transcription factors/initiators resulting in the transcription of BMP target genes involved in 
the cell cycle, proliferation and self-renewal [1, 2]. 
The role of BMP pathway in the maintenance of pluripotency 
Human and mouse embryonic stem cells (ESCs) maintain their pluripotency through the expression of 
a complex transcription factor network with the key transcription factors being; Oct4, Nanog, Sox2, 
Klf4, Rex1 and Cited2 [3]. Several signalling pathways co-ordinate this transcriptional network, with the 
TGFβ superfamily signalling pathway contributing to the maintenance of pluripotency and early 
differentiation decisions [4].  Transcriptome analyses of human ESCs (hESCs) cultured on feeder cells 
revealed these cells require signals mediated by fibroblast growth factor 2 (FGF2), activin, TGFβ, 
insulin, and insulin-like growth factor (IGF) to maintain their undifferentiated state [5]. In hESCs TGFβ 
and FGF2 cooperate to inhibit BMP signalling and sustain the expression of pluripotency markers, 
especially via activated SMAD3 binding to the NANOG promoter. Activation of SMAD2/3 signals is 
required as a downstream event to maintain the undifferentiated state of hESCs [4, 6]. On the other 
hand the proximal NANOG promoter contains the TGFβ/activin responsive element, which is 
negatively regulated by signals from the BMP pathway.  Xu et al. demonstrated that culturing hESCs in 
high amounts of FGF2 in combination with inhibiting the BMP pathway using the BMP antagonist 
noggin (NOG) maintains pluripotency and long term, undifferentiated proliferation of hESCs [4, 7]. 
FGF2 maintains hESCs by activating the MAPK pathways while the signals mediated by Activin/Nodal 
and IGF maintain pluripotency via activation of Ras and phosphatidylinositol-3 kinase (PI3K) pathways 
[4, 7] (Figure 1).  
In murine ES cells (mESCs) self-renewal capacity can be maintained by the cytokine leukaemia 
inhibitory factor (LIF) [8]. However, the presence of LIF is not totally sufficient as the cells also require 
the presence of foetal calf serum to maintain pluripotency. It was shown that the BMPs present in the 
serum are the key additional signalling molecules which act in conjunction with LIF, enhancing the self-
renewal and pluripotency of mESCs [4, 9]. Further work revealed that activation of the BMP pathway 
through BMP4 stimulation leads to the expression of inhibitor of differentiation gene 1 (Id1), critical for 
suppressing ESC differentiation and sustaining pluripotency [9]. This is supported by other studies 
showing that overexpression of Id1 encourages mESCs to self-renew in the absence of BMP4, with 
suppression of Id1 leading to decreased Nanog expression, which results in the failure of mESCs to 
maintain self-renewal [10]. 
BMP pathway and the initiation and maintenance of embryonic haemopoiesis 
BMP signalling plays a key role during early embryogenesis and subsequent organogenesis. The 
BMP and Wnt pathways are essential for mesodermal patterning and subsequent specification of 
haemopoiesis in the developing embryo [11]. Haemopoietic and endothelial cells are among the 
earliest cells to form in the embryo, with BMP pathway involvement in the initiation of this process 
conserved throughout evolution [11, 12]. These cells arise during gastrulation from mesodermal 
progenitors in the epiblast [13]. Studies using targeted gene disruption in murine models revealed 
BMP2 [14], BMP4 [15], anaplastic lymphoma kinase 3 (ALK3) [12] and BMP type II receptor (BMPRII) 
[16] play important roles in early haemopoiesis as all these defects cause early embryonic lethality 
and reduced formation of mesoderm. In particular, BMP4 plays a key role in mesoderm induction and 
haemopoietic commitment, and is fundamental for inducing haemopoietic differentiation in murine [17] 
and human [18] ESCs in vitro. In mESCs BMP4 induces the formation of mesoderm and early 
haemopoietic precursors whereas inhibition of BMP signalling impaired haemopoietic development 
[17, 19]. In hESCs, BMP4 in combination with cytokines also enhanced haemopoietic differentiation 
[18]. Developmental studies indicate that the BMP and Wnt pathways converge to regulate the Cdx 
family of homeobox transcription factors, master regulators of Hox gene expression [20, 21].  
Activation of BMP pathway induces Wnt3a and thereby the canonical Wnt pathway, which in turn 
activates the Cdx-Hox axis [21]. Furthermore in mESCs overexpression of Cdx1 and Cdx4 induces 
Wnt3a suggesting that Wnt signalling also acts downstream of Cdx proteins [21]. Studies from zebra 
fish and mESCs indicate that Cdx-driven patterning is necessary for the development of mesoderm 
derivatives such as the haemopoietic system [20, 21]. During early development Cdx genes show a 
similar expression pattern to Hox genes. In mice, this expression is detected in the posterior epiblast 
and the overlaying mesoderm at the posterior end of the primitive streak. As reviewed by Lengerke 
and Daley during the development in the posterior trunk zone, anterior trunk tissues are exposed to 
Cdx genes but as cells move anteriorly, Cdx transcripts decrease [20]. Cdx genes expression persists 
in the posterior region of the embryo. This is then followed by the expression of more posterior Hox 
genes which enables the development of posterior trunk mesoderm and tail. Cdx4-deficient mice have 
been shown to produce reduced numbers of yolk sac-derived erythroid colonies [20].  
Primitive haemopoiesis during murine development takes place in the yolk sac between E7 and E11, 
whereas in the human system primitive erythropoiesis is initiated in the yolk sac around week 3 of 
gestation and remains active until week 6.  During mammalian development, BMP4 is involved in the 
induction of the yolk sac haemopoietic program. It has been shown that signals from the visceral 
endoderm, such as Indian hedgehog (Hh), are critical for the development of the yolk sac 
haemopoietic program and the regulation of BMP4 expression [22]. Mouse studies illustrate BMP4 
knockout mice die between E7.5 and E9.5 exhibiting severe defects in mesoderm formation and the 
embryos that survive up to E9.5 show defective blood islands [15]. Studies on other components of 
BMP pathway further highlight the role of this family in haemopoietic development. Disruption of the 
Smad5 gene in mice leads to severe defects in yolk sac circulation and subsequent death around 
mid-gestation [20]. Yolk sacs from these embryos (Smad5−/− E9.0 to 9.5 yolk sac) have increased 
numbers of high-proliferative potential colony forming cells (HPP-CFCs) with enhanced re-plating 
potential. These data suggest that Smad5 transduces signals that inhibit the early specification events 
of haemopoietic precursors as well as their subsequent expansion [21].  
Primitive yolk sac haemopoiesis is then replaced by the definitive, HSCs derived multi-lineage blood 
system that is sustained throughout life [23]. The area of the embryo known as the para-aortic 
splanchnopleura (P-Sp), E8.5-9.5 in the mouse, is the first site to produce haemopoietic progenitors 
with myeloid and lymphoid potential [24], however these cells are unable to sustain long term 
reconstitution of irradiated recipients [25]. The P-Sp gives rise to the developing aorta, gonads and 
mesonephros (AGM) region by E10-11.5 [26].  The AGM is the site where the first definitive HSCs 
arise, these emerge as clusters of cells from the ventral wall of the dorsal aorta from E10.5, these 
cells are multipotent and display long term reconstitution potential [27-29]. In mouse and human 
embryos, BMP4 is expressed in the mesenchyme underlying the aorta and is required for HSC 
maintenance [30-32]. It has been shown using BMP responsive element (BRE) green fluorescent 
protein (GFP) transgenic mouse embryos that the first HSCs emerging in vivo in the AGM region are 
GFP+ i.e. BMP activated and have long term reconstituting potential. However the proportion of BMP 
activated HSCs decreases through ontogeny, with approximately three quarters of the HSCs in the 
foetal liver (FL) being GFP+ BMP activated whereas the majority of HSCs found in the bone marrow 
(BM) are GFP- i.e. non-BMP activated.  The two types of HSCs found in the FL and BM display 
distinct differences in their lineage output and their intrinsic molecular programs, with BMP activated 
HSCs favouring a more myeloid-lymphoid balanced differentiation programme [33]. Explant studies 
using E11 AGM have revealed that over the 3 day culture period GFP- non-BMP activated HSCs 
emerge and these cells are controlled by the Hh/Vascular Endothelial Growth Factor (VEGF) 
pathway. Elegant transplantation experiments and transcriptome data indicate that the GFP+ BMP 
activated HSCs can give rise to the GFP- Hh/VEGF responsive HSCs, with the GFP+ expressing a 
more haemogenic endothelial molecular program, whereas the GFP- express a haemopoietic program 
[34]. As in the mouse, the AGM region in humans contains definitive haemopoietic cells prior to their 
detection in the FL [35]. Between E12-13 in the mouse, the HSCs migrate and populate the 
developing FL, which becomes the principal site of haemopoiesis throughout the remainder of foetal 
life. Whereas in humans the FL continues as a major site of haemopoiesis until week 22, by which 
time the foetal bones, which start to become colonised by HSCs in weeks 8–12, then takes over as 
the major site of haemopoiesis [35]. By birth the BM is established as the major site of haemopoiesis 
and continues as the major source of haemopoietic cells throughout life. In adults the embryonic 
morphogens including the TGFβ superfamily play an important role in maintaining haemopoietic 
homeostasis.  Osteoblasts, stromal cells, megakaryocytes and platelets all secrete BMPs, which have 
been implicated in the self-renewal and maintenance of HSCs, as well as regulating the expansion of 
progenitor cells and their differentiation into the mature lineages of the haemopoietic system [36] 
(Figure 2). 
Reactivation of embryonic pathways in leukaemia 
HSCs have three key properties of long life, multipotency and self-renewal. Within the BM, control of 
steady state haemopoiesis is regulated by extrinsic and intrinsic factors which control the balance 
between HSC self-renewal and differentiation. Cell extrinsic cues are governed by the stem cell niche 
and include growth factors, cytokines, chemokines, oxygen tension, nutrients and cell-to-cell 
interactions with stroma, endothelium, osteoblasts and the extra-cellular matrix. These signals merge 
into a network of intrinsic regulators resulting in the activation of signalling pathways, induction of 
transcription factors and changes to epigenetic marks [37, 38]. All of which govern the balance 
between self-renewal and differentiation of HSCs. Recent evidence indicates that important regulatory 
networks involved in establishing primitive and definitive haemopoiesis during development are 
reactivated in leukaemias, giving rise to a LSC population with altered self-renewal and differentiation 
properties. In particular altered activation of the conserved embryonic morphogenic pathways 
including; Wnt, Hedgehog, BMP, TGFβ, and Notch as well as the Cdx-Hox transcription factors and 
the BMI1/ polycomb transcriptional regulators is becoming an emerging theme in myeloid leukaemia 
[37]. In mixed lineage leukaemia (MLL) it has been shown that the LSCs are maintained in a self-
renewing state through expression of a transcription program more akin to ESCs, than adult stem 
cells and that the LSCs occupy the apex of a leukaemia cell hierarchy, supporting the cancer stem 
cell model of disease [39].  
Role of BMP pathway in leukaemia and leukaemic stem cells (LSCs) 
BMP ligands are naturally produced and secreted by cells in the BM microenvironment [36]. There are 
more than 500 genes controlled by BMP and TGFβ pathways, which are involved in HSC 
maintenance and self-renewal [40]. TGFβ signalling is important for HSC quiescence through its anti-
proliferative properties, as well as immune cell homeostasis and its ability to decrease meylopoiesis. 
BMPs are known to regulate HSCs self-renewal and differentiation through intrinsic and extrinsic 
mechanisms [41]. BMP2, BMP4, BMP7 and Smad proteins have been implicated in the self-renewal 
and maintenance of HSCs, expansion of progenitor cells and their differentiation into the mature 
lineages of the haemopoietic system [42, 43]. In normal haemopoiesis BMP2, BMP4 and BMP7 
regulate proliferation, maintenance, clonogenicity and repopulating activities of immature blood 
progenitors [44]. 
Given the important roles BMPs play in stem cell biology and haemopoiesis it is surprising that 
deregulation of this pathway has only been shown to occur in two types of leukaemia to date; namely 
acute promyelocytic leukaemia (APL)  [45] and CML [36, 46]. However recent research has started to 
focus on the leukaemic BM niche, especially the leukaemic endosteal niche. In many myeloid 
leukaemias there is enhanced osteoblastic proliferation and a marked increase in LSCs and 
progenitor expansion [37, 46]. LSCs strongly rely on the BM niche for their self-renewal and 
proliferation and may also modify it to their advantage. Recent research on the role of the 
microenvironment in CML confirms elevated levels of BMPs in the BM of chronic phase (CP) patients 
[46]. This study illustrates that deregulation of the BMP pathway may lead to HSC expansion due to 
exposure of CD34+ cells which overexpress BMPR1B (ALK6) to the increased amount of soluble 
BMP2/ BMP4 in the BM [46]. Moreover transcriptome studies of CML LSCs and progenitors indicate 
that the TGFβ and BMP pathways are downregulated in CP CML which suggests an extrinsic 
mechanism for TGFβ involvement in this disease [46]. Deregulation of this pathway has also been 
shown in murine models where Bmpr1a/Alk3 conditional knockout mouse have impaired BMP 
signalling, which leads to increased niche size and thereby enhanced numbers of HSCs [47].  
Although the BMP pathway hasn’t been directly linked to many myeloid malignancies, its downstream 
target genes, the Cdx-Hox axis are an emerging theme in leukaemia (Figure 3). It is known that Wnt 
and BMP signalling converge to regulate the Cdx family of homeobox transcription factors, master 
regulators of Hox gene expression [21, 48]. Wnt/GSK3β/-βcatenin signalling, which plays an important 
role in HSC homeostasis is altered in blast-crisis CML [37, 49]. Increased levels of active β-catenin 
and components of the Wnt pathway have also been shown to occur in AML patients, with the 
enhanced re-plating capacity of these LSCs abrogated by inhibiting Wnt signalling [37, 50]. 
Consensus binding sites for the three Cdx homologues Cdx1, Cdx2, and Cdx4 are present in the 
promoters of multiple HOX genes [51]. Cdx2 is aberrantly expressed in AML and promotes 
leukemogenesis via deregulation of Hox genes [52]. The study by Scholl et al. indicated that CDX2 is 
overexpressed in 90% of patients with AML [52]. In this study, overexpression of Cdx2 in primary 
murine haemopoietic progenitors resulted in transplantable AML in vivo, coinciding with a three-fold 
up regulation in Hoxb6 expression. Interestingly, overexpression of HOXB6 has been documented in 
approximately 40% of human AMLs that do not have chromosomal translocations [53]. Furthermore 
other family members of CDX2 such as CDX1, and CDX4 are direct targets of the Wnt pathway and 
are up regulated in AML [52]. 
Substantial evidence has now linked aberrant expression of HOX genes to the pathogenesis of 
myeloid malignancies, especially AML and CML [54, 55]. HOX genes have been reported to be 
deregulated in AML through several different mechanisms. Fusions of the HOXA9 or HOXD13 genes 
with NUP98, a gene that encodes a component of the nuclear pore complex, have been described in 
AML, and recapitulates AML in murine models of disease [55-57].  Furthermore overexpression of 
HOXA6, HOXA7, HOXA9, and the HOX co-factor MEIS1 has also been correlated with chromosome 
11q23 abnormalities involving the MLL protein, which regulates the expression of HOX genes [58]. 
The t(8;16)(p11;p13) translocation in AML, results in the expression of the MYST3-CREBBP fusion 
protein and the up regulation of HOXA9, HOXB9, HOXA10, and MEIS1 [59].  In addition, the 
expression of HOXC4 was shown to be up regulated in the NB4 PML-RARα cell line following all-trans 
retinoic acid–induced (ATRA-induced) differentiation as well as in BM from acute promyelocytic 
leukaemia (PML) patients during ATRA treatment [60]. Over expression of individual Hox family 
members, including HoxB3 [61], HoxB8 [62], or HoxA10 [61], by retroviral expression or retroviral 
insertion mutagenesis also generates AML in murine models. In addition up regulation of specific Hox 
genes, such as HoxB4 or HoxA9, is associated with expansion of the HSC compartment in vitro and in 
vivo and results in enhanced competitive repopulating activity in murine transplantation experiments 
[63, 64]. Changes in Hox gene expression patterns have also been linked to clinical variables in 
myeloid leukaemias, most notably in CML, where hypermethylation of HOXA5 and HOXA4 strongly 
correlates with progression to blast crisis [65]. Considering both the BMP and Wnt signalling pathways 
are known to be deregulated in CML, it is feasible to speculate that the elevated BMP ligands 
observed in the BM of the CML patients [46] may alter the Cdx-Hox gene axis resulting in an altered 
balance in LSCs self-renewal and myelopoiesis.  
Overall these data demonstrate the BMP signalling pathway plays a fundamental role during 
embryogenesis and haemopoietic ontogeny. This family of morphogens act at multiple levels during 
development, starting at the earliest stage by influencing pluripotent stem cell self-renewal, followed by 
mesodermal specification, then later on during the establishment of primitive and definitive 
haemopoiesis in the embryo and finally playing a role in haemopoietic equilibrium in the adult. 
Evidence from the literature indicates that BMP activation of HSCs during AGM emergence in the 
murine setting may sustain their myeloid-lymphoid differentiation potential as they migrate and expand 
within different anatomical sites during development. Interestingly by the time the HSCs populate the 
BM the majority are no longer BMP activated, which could potentially reflect cell autologous changes 
or the influence of the different extrinsic signals within the FL and BM microenvironments. The 
influence of BMP signalling on lineage specification has important implications for leukaemia and may 
enhance our understanding in the future as to why paediatric leukaemia is predominantly lymphoid 
whereas adult leukaemia is predominantly myeloid. Future studies will unravel the complexities of how 
altered BMP signalling within the malignant haemopoietic niche perturbs the equilibrium to aid aberrant 
haemopoiesis and the development of disease.  
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Figure 1. Maintenance of pluripotency in mouse and human stem cells. In human ESCs (hESCs) inhibition of 
BMP4 via the action of fibroblast growth factor 2 (FGF2) and noggin (NOG), phosphorylation of SMAD2/3, and 
activation of the PI3K/AKTpathway and stabilisation of β-catenin have been suggested to be crucial for the 
maintenance of pluripotency. Downregulation of NANOG and OCT4 results in differentiation of hESCs to 
extraembryonic lineages (ectoderm and endoderm), indicating that each of these transcription factors is important 
for the maintenance of pluripotency. TGFβ/Nodal/Activin signalling pathways inhibit differentiation to ectoderm and 
promote pluripotency in hESCs. In murine embryonic stem cells (mESCs) Bone morphogenetic protein 4 (BMP4) 
and leukaemia inhibitory factor (LIF) signalling are required to maintain the pluripotency under serum-free culture 
conditions. BMP4 signalling activates the expression of inhibitor of DNA binding (Id) genes through the 
phosphorylation of downstream smads 1/5/8. This inhibits mESC differentiation to neuroectoderm. LIF signalling 
results in activation of transcription factors (Jak/Stat3) and suppression of differentiation to endodermal and 
mesodermal lineages. Nanog and Oct4 action is required for both the self-renewal of mESCs and maintenance of 
pluripotency since their down regulation results in differentiation towards extraembryonic lineages and loss of self-
renewal (pink arrows: interaction between the components, blue arrows: activation, blunt end lines: inhibition, 
dotted lines: indirect effect). 
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 Figure 2. Haemopoietic development timeline in mouse and human. The site of primary haemopoiesis in the 
embryo is transient which means that it changes during development. This process involves several anatomical 
sites (the yolk sac, the aorta-gonad-mesonephros region, the placenta and the foetal liver), after which HSCs 
colonize the bone marrow. Mesoderm is formed during gastrulation. Commitment of posterior mesoderm to 
haemangioblasts occurs at a very early stage in the primitive streak. Primitive haemopoiesis and vasculogenesis 
become specified from the haemangioblasts where commitment of mesodermal progenitors to the haemopoietic 
and endothelial lineages begins. This is then followed by development of yolk sac blood islands. Definitive 
haemopoiesis is initiated by the emergence of HSCs in the AGM region as well as in large arteries and placenta. 
HSCs then migrate and expand in the foetal liver followed by the bone marrow of the late gestation foetus. Pre-
HSCs undergo a maturation process that allows them to engraft, survive and self-renew in future haemopoietic 
niches. Subsequently, foetal HSCs expand rapidly, after which a steady state is established in which HSCs 
reside in a relatively quiescent state in the bone marrow after birth (time line on the left of the diagram correlates 
with the schematic presentation on the right of the diagram. Block colour arrows illustrate the haemopoietic sites 
being consistently active whereas colour gradient arrows show the site loses its role during haemopoietic 
ontogeny). 
 
  
 Figure 3. Main morphogenic signalling pathways activating Hox genes. Posterior HOX genes are 
predominantly activated by canonical Wnt and non-canonical BMP pathways. In the presence of Wnt ligand, Wnt 
binds to frizzled (FZD) receptor and LRP5/6 co-receptor and activates dishevelled (DVL), leading to the inhibition 
of APC/Axin/GSK3β-mediated β-catenin degradation. Phosphorylated SMAD1/5/8 through non-canonical BMP 
pathway form a complex with stabilised β-catenin and LEF1 at the promoter region of posterior HOX genes and 
regulate their expression with the aid of Cdx family members. 
 
